Rocket Historical Balance Sheet

RCKT Stock

USD 14.20 0.09 0.64%

Trend analysis of Rocket Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 517.2 M, Current Deferred Revenue of 10.6 M, Accounts Payable of 1.7 K or Cash of 53.1 M provides information on Rocket Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Rocket Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Rocket Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Rocket Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Rocket Pharmaceuticals is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.

About Rocket Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Rocket Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Rocket Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Rocket Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Rocket currently owns. An asset can also be divided into two categories, current and non-current.

Rocket Pharmaceuticals Balance Sheet Chart

At this time, Rocket Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 1.5 B in 2024, despite the fact that Retained Earnings are likely to grow to (911.4 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Current Deferred Revenue Intangible Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of Rocket Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Rocket Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Rocket Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Rocket Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most accounts from Rocket Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Rocket Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rocket Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Rocket Stock please use our How to Invest in Rocket Pharmaceuticals guide.At this time, Rocket Pharmaceuticals' Non Current Liabilities Total is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 1.5 B in 2024, despite the fact that Retained Earnings are likely to grow to (911.4 M).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	22.6M	22.9M	25.0M	30.8M
Total Assets	497.0M	551.8M	566.3M	292.8M

Short Long Term Debt Total Total Assets

Rocket Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Long Term Debt
Total Assets		0.54	0.81	0.83	0.95	-0.24	-0.77	-0.69	0.36	0.8	0.84	0.8	0.99	0.91	0.88	-0.09	0.96	0.84	0.63	0.99	0.69	0.89	0.41	0.99	-0.18	0.64
Short Long Term Debt Total	0.54		0.38	0.37	0.49	0.05	-0.46	-0.19	-0.04	0.63	0.29	0.4	0.62	0.51	0.42	0.57	0.57	0.36	0.73	0.62	0.18	0.45	-0.09	0.54	-0.48	0.89
Other Current Liab	0.81	0.38		0.99	0.92	-0.06	-0.37	-0.92	0.32	0.39	0.98	0.67	0.76	0.91	0.97	-0.16	0.73	0.97	0.59	0.76	0.55	0.96	0.82	0.81	0.25	0.55
Total Current Liabilities	0.83	0.37	0.99		0.93	-0.06	-0.41	-0.92	0.32	0.42	0.98	0.68	0.78	0.91	0.96	-0.16	0.76	0.98	0.6	0.78	0.63	0.95	0.81	0.82	0.24	0.52
Total Stockholder Equity	0.95	0.49	0.92	0.93		-0.14	-0.7	-0.81	0.31	0.71	0.93	0.75	0.94	0.98	0.96	-0.18	0.91	0.94	0.56	0.94	0.66	0.97	0.56	0.96	-0.08	0.61
Current Deferred Revenue	-0.24	0.05	-0.06	-0.06	-0.14		0.23	0.05	-0.95	-0.2	-0.19	-0.18	-0.17	-0.07	-0.06	0.14	-0.33	-0.08	-0.03	-0.18	-0.13	-0.09	-0.13	-0.17	-0.04	-0.04
Net Debt	-0.77	-0.46	-0.37	-0.41	-0.7	0.23		0.2	-0.17	-0.98	-0.43	-0.64	-0.83	-0.63	-0.55	0.06	-0.84	-0.43	-0.33	-0.83	-0.6	-0.54	0.13	-0.79	0.53	-0.38
Retained Earnings	-0.69	-0.19	-0.92	-0.92	-0.81	0.05	0.2		-0.34	-0.21	-0.93	-0.49	-0.62	-0.79	-0.86	0.31	-0.59	-0.96	-0.41	-0.62	-0.5	-0.86	-0.87	-0.69	-0.26	-0.45
Accounts Payable	0.36	-0.04	0.32	0.32	0.31	-0.95	-0.17	-0.34		0.14	0.43	0.27	0.26	0.25	0.27	-0.23	0.4	0.33	0.12	0.27	0.21	0.31	0.43	0.29	0.19	0.12
Cash	0.8	0.63	0.39	0.42	0.71	-0.2	-0.98	-0.21	0.14		0.43	0.65	0.86	0.66	0.56	0.08	0.86	0.44	0.45	0.86	0.56	0.56	-0.15	0.81	-0.58	0.53
Non Current Assets Total	0.84	0.29	0.98	0.98	0.93	-0.19	-0.43	-0.93	0.43	0.43		0.69	0.78	0.9	0.97	-0.23	0.77	0.98	0.54	0.78	0.63	0.95	0.82	0.83	0.25	0.49
Non Currrent Assets Other	0.8	0.4	0.67	0.68	0.75	-0.18	-0.64	-0.49	0.27	0.65	0.69		0.78	0.75	0.76	0.13	0.76	0.64	0.67	0.78	0.53	0.72	0.33	0.79	-0.01	0.45
Cash And Short Term Investments	0.99	0.62	0.76	0.78	0.94	-0.17	-0.83	-0.62	0.26	0.86	0.78	0.78		0.91	0.85	-0.04	0.97	0.79	0.62	1.0	0.67	0.87	0.3	0.99	-0.3	0.67
Common Stock Total Equity	0.91	0.51	0.91	0.91	0.98	-0.07	-0.63	-0.79	0.25	0.66	0.9	0.75	0.91		0.96	-0.19	0.85	0.92	0.53	0.91	0.52	0.99	0.56	0.93	-0.08	0.66
Common Stock Shares Outstanding	0.88	0.42	0.97	0.96	0.96	-0.06	-0.55	-0.86	0.27	0.56	0.97	0.76	0.85	0.96		-0.16	0.81	0.96	0.58	0.85	0.59	0.98	0.68	0.89	0.12	0.59
Non Current Liabilities Total	-0.09	0.57	-0.16	-0.16	-0.18	0.14	0.06	0.31	-0.23	0.08	-0.23	0.13	-0.04	-0.19	-0.16		-0.03	-0.23	0.66	-0.04	-0.04	-0.22	-0.33	-0.14	-0.1	0.31
Other Current Assets	0.96	0.57	0.73	0.76	0.91	-0.33	-0.84	-0.59	0.4	0.86	0.77	0.76	0.97	0.85	0.81	-0.03		0.76	0.62	0.97	0.75	0.82	0.31	0.95	-0.23	0.59
Other Stockholder Equity	0.84	0.36	0.97	0.98	0.94	-0.08	-0.43	-0.96	0.33	0.44	0.98	0.64	0.79	0.92	0.96	-0.23	0.76		0.52	0.79	0.6	0.96	0.78	0.84	0.13	0.57
Total Liab	0.63	0.73	0.59	0.6	0.56	-0.03	-0.33	-0.41	0.12	0.45	0.54	0.67	0.62	0.53	0.58	0.66	0.62	0.52		0.63	0.49	0.53	0.28	0.58	0.04	0.65
Total Current Assets	0.99	0.62	0.76	0.78	0.94	-0.18	-0.83	-0.62	0.27	0.86	0.78	0.78	1.0	0.91	0.85	-0.04	0.97	0.79	0.63		0.67	0.87	0.31	0.99	-0.3	0.67
Short Term Debt	0.69	0.18	0.55	0.63	0.66	-0.13	-0.6	-0.5	0.21	0.56	0.63	0.53	0.67	0.52	0.59	-0.04	0.75	0.6	0.49	0.67		0.52	0.33	0.67	0.06	0.1
Common Stock	0.89	0.45	0.96	0.95	0.97	-0.09	-0.54	-0.86	0.31	0.56	0.95	0.72	0.87	0.99	0.98	-0.22	0.82	0.96	0.53	0.87	0.52		0.67	0.9	0.03	0.62
Other Liab	0.41	-0.09	0.82	0.81	0.56	-0.13	0.13	-0.87	0.43	-0.15	0.82	0.33	0.3	0.56	0.68	-0.33	0.31	0.78	0.28	0.31	0.33	0.67		0.39	0.64	0.16
Net Tangible Assets	0.99	0.54	0.81	0.82	0.96	-0.17	-0.79	-0.69	0.29	0.81	0.83	0.79	0.99	0.93	0.89	-0.14	0.95	0.84	0.58	0.99	0.67	0.9	0.39		-0.23	0.64
Other Assets	-0.18	-0.48	0.25	0.24	-0.08	-0.04	0.53	-0.26	0.19	-0.58	0.25	-0.01	-0.3	-0.08	0.12	-0.1	-0.23	0.13	0.04	-0.3	0.06	0.03	0.64	-0.23		-0.35
Long Term Debt	0.64	0.89	0.55	0.52	0.61	-0.04	-0.38	-0.45	0.12	0.53	0.49	0.45	0.67	0.66	0.59	0.31	0.59	0.57	0.65	0.67	0.1	0.62	0.16	0.64	-0.35

Click cells to compare fundamentals

Rocket Pharmaceuticals Account Relationship Matchups

Rocket Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	372.1M	590.8M	497.0M	551.8M	566.3M	292.8M
Short Long Term Debt Total	47.4M	61.7M	22.6M	22.9M	25.0M	30.8M
Other Current Liab	16.8M	23.2M	17.1M	34.2M	43.1M	45.2M
Total Current Liabilities	18.3M	32.6M	22.2M	39.2M	48.5M	50.9M
Total Stockholder Equity	307.3M	503.5M	454.7M	489.7M	492.6M	517.2M
Current Deferred Revenue	562K	590K	(482.0)	(36.7M)	10.1M	10.6M
Net Debt	(137.9M)	(235.4M)	(210.1M)	(117.7M)	(30.9M)	(32.4M)
Retained Earnings	(183.1M)	(322.8M)	(491.9M)	(713.8M)	(959.4M)	(911.4M)
Accounts Payable	340.0	835.0	482.0	36.7M	1.8K	1.7K
Cash	185.4M	297.1M	232.7M	140.5M	55.9M	53.1M
Non Current Assets Total	64.4M	103.5M	105.0M	187.7M	188.1M	197.5M
Non Currrent Assets Other	2.0M	2.0M	1.8M	1.9M	1.9M	1.2M
Cash And Short Term Investments	304.1M	482.7M	388.7M	356.4M	373.2M	226.1M
Common Stock Total Equity	452K	548K	610K	645K	741.8K	778.8K
Common Stock Shares Outstanding	49.0M	55.4M	63.2M	68.1M	84.0M	88.2M
Liabilities And Stockholders Equity	372.1M	590.8M	497.0M	551.8M	566.3M	292.8M
Non Current Liabilities Total	46.5M	54.7M	20.1M	23.0M	25.3M	29.4M
Other Current Assets	3.6M	9.3M	6.6M	7.7M	5.0M	3.6M
Other Stockholder Equity	489.9M	825.8M	946.2M	1.2B	1.5B	1.5B
Total Liab	64.8M	87.3M	42.3M	62.1M	73.8M	59.0M
Total Current Assets	307.8M	487.3M	392.1M	364.1M	378.2M	229.0M
Accumulated Other Comprehensive Income	20K	(42K)	(161K)	(357K)	319K	335.0K
Short Term Debt	957K	9.4M	5.1M	5.0M	5.4M	3.5M
Common Stock	548K	610K	645K	791K	903K	948.2K
Other Liab	23K	136K	80K	2.6M	3.0M	3.1M
Net Tangible Assets	307.3M	503.5M	454.8M	424.8M	488.5M	252.1M
Long Term Debt	49.5M	41.4M	45.0M	35.1M	40.3M	35.0M
Property Plant And Equipment Net	31.3M	70.6M	72.3M	77.6M	87.6M	92.0M
Retained Earnings Total Equity	(105.9M)	(183.1M)	(322.8M)	(491.9M)	(442.7M)	(420.6M)
Short Term Investments	118.7M	185.6M	156.0M	215.9M	317.3M	333.1M
Capital Surpluse	300.3M	489.9M	825.8M	946.2M	1.1B	549.2M
Property Plant And Equipment Gross	31.3M	70.6M	77.6M	86.7M	101.6M	106.7M
Property Plant Equipment	29.3M	19.2M	72.3M	77.6M	89.3M	93.8M
Long Term Debt Total	49.5M	41.4M	45.0M	35.1M	31.6M	35.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Rocket Historical Balance Sheet

About Rocket Balance Sheet Analysis

Rocket Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Current Deferred Revenue

Intangible Assets

Rocket Pharmaceuticals balance sheet Correlations

Rocket Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Rocket Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Rocket Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Net Tangible Assets	+ 0.99	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Accounts Payable	- 0.95	Current Deferred Revenue
Non Current Assets Total	- 0.93	Retained Earnings
Retained Earnings	- 0.92	Total Current Liabilities
Retained Earnings	- 0.92	Other Current Liab